ACHL News and Press, Achilles Therapeutics plc From 11/30/22

- Durable partial response (PR) and stable disease (SD) achieved in heavily pre-treated non-small cell lung cancer (NSCLC) patients dosed with cNeT monotherapy - - Updated interim Phase I/II results show encouraging safety and tolerability profile with potential for deep and durable respons...

LONDON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that United States (US) patent 11,504,398 has been granted. The patent cover...

Achilles Therapeutics press release ( NASDAQ: ACHL ): Q3 GAAP EPS of -$0.32 beats by $0.33 . Cash and cash equivalents were $179.9 million as of September 30, 2022, as compared to $266.3 million as of December 31, 2021. For further details see: Achilles Thera...

- Interim update from the ongoing Phase I/IIa trials in advanced NSCLC (CHIRON) and melanoma (THETIS) to be presented at the ESMO Immuno-Oncology Annual Congress 2022 - - Strong cash balance of $179.9 million supports all planned operations into Q2 2025 - LONDON, Nov. 08, 2022 (GL...

Professor Swanton joins Achilles SAB member Dr. Christopher Klebanoff and Dr. John Haanen on the key opinion leader panel to discuss neoantigens as valuable immunotherapy targets Virtual Roundtable to take place on Thursday, October 13, 2022 at 12:30 PM ET / 5:30 PM UK LONDON, Oct...

Achilles Therapeutics press release ( NASDAQ: ACHL ): Q2 GAAP EPS of -$0.44 beats by $0.13 . Cash and cash equivalents: Cash and cash equivalents were $201.6 million as of Q2 For further details see: Achilles Therapeutics GAAP EPS of -$0.44 beats by $0.13

- Additional clinical data from the ongoing Phase I/IIa trials in advanced NSCLC (CHIRON) and melanoma (THETIS) expected to be available in Q4 2022 - - Cell & Gene Therapy Catapult manufacturing facility approved by MHRA for cNeT production in CHIRON and THETIS clinical trials - ...

Achilles Therapeutics ( NASDAQ: ACHL ) said it is leading a consortium which has been awarded a €4M grant under an EU program to develop a smart bioprocessing manufacturing platform for personalized cell therapies. The company said Horizon Europe — an EU ...

LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that it is leading a consortium that has been awarded a €4 million ($4.2 million...

LONDON, June 30, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of James Taylor as Chief Business Officer and Cassian Yee, MD to its Sc...